CA2522980A1 - Derives de wortmannine solubles dans l'eau - Google Patents

Derives de wortmannine solubles dans l'eau Download PDF

Info

Publication number
CA2522980A1
CA2522980A1 CA002522980A CA2522980A CA2522980A1 CA 2522980 A1 CA2522980 A1 CA 2522980A1 CA 002522980 A CA002522980 A CA 002522980A CA 2522980 A CA2522980 A CA 2522980A CA 2522980 A1 CA2522980 A1 CA 2522980A1
Authority
CA
Canada
Prior art keywords
alkyl
conjugate
formula
polymer
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CA002522980A
Other languages
English (en)
Inventor
Tianmin Zhu
Ker Yu
Judy Lucas
Jianxin Gu
Arie Zask
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2522980A1 publication Critical patent/CA2522980A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CA002522980A 2003-04-23 2004-04-20 Derives de wortmannine solubles dans l'eau Withdrawn CA2522980A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46479603P 2003-04-23 2003-04-23
US60/464,796 2003-04-23
PCT/US2004/012158 WO2004093918A2 (fr) 2003-04-23 2004-04-20 Derives de wortmannine solubles dans l'eau

Publications (1)

Publication Number Publication Date
CA2522980A1 true CA2522980A1 (fr) 2004-11-04

Family

ID=33310957

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002522980A Withdrawn CA2522980A1 (fr) 2003-04-23 2004-04-20 Derives de wortmannine solubles dans l'eau

Country Status (12)

Country Link
US (1) US20040213757A1 (fr)
EP (1) EP1615669A2 (fr)
JP (1) JP2006524289A (fr)
CN (1) CN1809385A (fr)
AR (1) AR044040A1 (fr)
AU (1) AU2004232308A1 (fr)
BR (1) BRPI0409681A (fr)
CA (1) CA2522980A1 (fr)
CL (1) CL2004000844A1 (fr)
MX (1) MXPA05011248A (fr)
TW (1) TW200503737A (fr)
WO (1) WO2004093918A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1799699A1 (fr) 2004-10-13 2007-06-27 Wyeth Analogues de la 17-hydroxywortmannine employés en tant qu inhibiteurs de pi3k
US7999023B2 (en) * 2004-12-03 2011-08-16 3M Innovative Properties Company Process for making pressure sensitive adhesive hydrogels
EP1940386A4 (fr) * 2005-09-01 2010-06-23 Beth Israel Hospital Conjugués de la wortmannine et utilisations de ceux-ci
EP2012794B1 (fr) * 2006-04-13 2014-09-17 The Trustees of Columbia University in the City of New York Compositions et dispositifs intraluminaux permettant d'inhiber la stenose vasculaire
US20090274739A1 (en) * 2006-04-13 2009-11-05 The Trustees Of Columbia University In The City Of New York Methods and compositions for treating neointimal hyperplasia
MX2009010683A (es) * 2007-04-05 2010-01-20 Wyeth Corp Conjugado de wortmanina-rapamicina y usos del mismo.
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
EP2576535A4 (fr) * 2010-06-04 2014-03-12 Oncothyreon Inc Polythérapies anticancéreuses utilisant des analogues de la wortmannine
PH12014500869A1 (en) 2011-10-19 2014-06-30 Signal Pharm Llc Treatment of cancer with tor kinase inhibitors
KR102040997B1 (ko) 2011-12-02 2019-11-27 시그날 파마소티칼 엘엘씨 7-(6-(2-히드록시프로판-2-일)피리딘-3-일)-1-((트랜스)-4-메톡시시클로헥실)-3,4-디히드로피라지노[2,3-b]피라진-2(1H)-온, 그의 고체 형태의 제약 조성물 및 그의 사용 방법
EP2817029B1 (fr) 2012-02-24 2019-07-10 Signal Pharmaceuticals, LLC Procédés de traitement du cancer du poumon non à petites cellules à l'aide d'une thérapie combinée d'inhibiteur de kinase
PE20151995A1 (es) 2013-01-16 2016-01-13 Signal Pharm Llc Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
WO2015160882A1 (fr) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Formes solides comprenant de la 7-(6- (2-hydroxypropan-2-yl) pyridin-3-yl)-1-(trans)-4-méthoxycyclohexyl)-3, 4-dihydropyrazino[2,3-b] pyrazin-2(1h)-one, et un co-formeur, leurs compositions et leurs procédés d'utilisation
WO2016010886A1 (fr) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Méthodes de traitement d'un cancer à l'aide de composés de pyrrolopyrimidine substitués, compositions de ceux-ci
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
TWI787284B (zh) 2017-06-22 2022-12-21 美商西建公司 以b型肝炎病毒感染表徵之肝細胞癌之治療

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4406793A (en) * 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
WO1994005283A1 (fr) * 1992-09-02 1994-03-17 Kyowa Hakko Kogyo Co., Ltd. Medicament anti-vih
US5378725A (en) * 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US5441947A (en) * 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
US5468773A (en) * 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5824701A (en) * 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5480906A (en) * 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
US5756593A (en) * 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US6331547B1 (en) * 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
ATE411321T1 (de) * 2000-09-19 2008-10-15 Wyeth Corp Wasserlösliche rapamycin-ester
US6399626B1 (en) * 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
MXPA04002445A (es) * 2001-09-14 2005-07-25 Univ Arizona Analogos de wortmanina y metodos para utilizar los mismos.
US20030194749A1 (en) * 2002-02-15 2003-10-16 Wandless Thomas J. Wortmannin derivatives as probes of cellular proteins and processes

Also Published As

Publication number Publication date
CN1809385A (zh) 2006-07-26
WO2004093918A3 (fr) 2005-03-24
AU2004232308A1 (en) 2004-11-04
TW200503737A (en) 2005-02-01
AR044040A1 (es) 2005-08-24
WO2004093918A2 (fr) 2004-11-04
JP2006524289A (ja) 2006-10-26
BRPI0409681A (pt) 2006-04-18
US20040213757A1 (en) 2004-10-28
EP1615669A2 (fr) 2006-01-18
MXPA05011248A (es) 2005-12-14
CL2004000844A1 (es) 2005-03-04

Similar Documents

Publication Publication Date Title
CA2522980A1 (fr) Derives de wortmannine solubles dans l'eau
Liang et al. Novel cathepsin B-sensitive paclitaxel conjugate: Higher water solubility, better efficacy and lower toxicity
CN101707888B (zh) 用7-乙基-10-羟基喜树碱的多臂聚合物缀合物治疗非霍奇金氏淋巴瘤
CN104955818B (zh) 核苷激酶旁路组合物和方法
TR201802093T4 (tr) Terapötik terapilerde kullanım için akt inhibitör bileşiği ve abirateron kombinasyonu.
KR20110089151A (ko) 항산화성 캠토테신 유도체 및 이들의 항산화성 항종양성 나노구체
CN113853368A (zh) 由支架部分制备的脂质缀合物
KR20180120746A (ko) 이카리인 및 이카리틴 유도체
EP3458448B1 (fr) Inhibiteurs de fasn pour utilisation dans le traitement de la stéatohépatite non alcoolique
JP2009520697A (ja) サイトカイン調節性を有する化合物
JPH07509248A (ja) ラパマイシン誘導体
WO2012092339A2 (fr) Conception de promédicaments libérables par hydrolyse pour des formulations de nanoparticules à libération prolongée
CN103814036B (zh) 喜树碱衍生物及其制备方法、药物组合物与用途
WO2015081821A1 (fr) Dérivés de rapamycine liés au polyéthylène glycol par un oligopeptide de cactus
US20040214799A1 (en) Cancerous metastasis inhibitors containing carbacyclic phosphatidic acid derivatives
WO2021041964A1 (fr) Inhibiteurs conjugués de la réponse à l'endommagement de l'adn
CN116870176B (zh) PSMA靶向的PSMA-PARPi偶联物及制备方法和应用
KR102246180B1 (ko) 핵 유전자 손상을 최소화한 암 치료를 위한 변형 항생제 화합물 및 이를 포함하는 항암 약학 조성물
US20250120928A1 (en) Suberoylanilide hydroxamic acid (saha) drugs, conjugates, and nanoparticles, and methods of use thereof
KR20200039756A (ko) MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR 및 MEK/PI3K/mTOR 생물학적 경로의 저해제 및 치료 화합물의 림프 흡수율, 생체이용률 및 용해도를 향상시키는 방법
Wang et al. Synthesis and evaluation of an injectable everolimus prodrug
CN113710660B (zh) Dot1l降解剂及其用途
KR102916585B1 (ko) 핵 유전자 손상을 최소화한 암 치료를 위한 미토콘드리아 표적 변형 항생제 화합물 및 이를 포함하는 항암 약학 조성물
KR20170091610A (ko) 신규 peg 유도체
CN111518157A (zh) 一种雷公藤甲素衍生物及其制备方法和应用

Legal Events

Date Code Title Description
EEER Examination request
AZWI Withdrawn application